Erythropoietic Protoporphyria (EPP) Treatment Market Global Report 2026

The erythropoietic protoporphyria (EPP) treatment market size has grown strongly in recent years. It will grow from $0.37 billion in 2025 to $0.4 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to limited therapeutic options for rare genetic phototoxic disorders, high misdiagnosis rates of erythropoietic protoporphyria, reliance on symptom-based pain management therapies, lack of targeted biologic treatments for heme metabolism disorders, low awareness of rare metabolic diseases among clinicians.

The erythropoietic protoporphyria (EPP) treatment market size is expected to see strong growth in the next few years. It will grow to $0.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to advancements in gene therapy and precision medicine approaches, increasing investment in orphan drug development programs, growing adoption of personalized treatment strategies for rare diseases, improved diagnostic technologies enabling early detection of erythropoietic protoporphyria, and rising focus on photoprotection and dermatological innovation. Major trends in the forecast period include gene-targeted therapies for erythropoietic protoporphyria management and symptom reduction, advanced photoprotection formulations preventing light-induced skin damage, development of heme biosynthesis pathway modulators for disease control, personalized precision medicine approaches for rare genetic disorder treatment, and wearable light exposure monitoring systems enabling patient-driven symptom prevention.

The increasing healthcare expenditure is expected to propel the growth of the erythropoietic protoporphyria (EPP) treatment market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, pharmaceuticals, healthcare infrastructure, and patient care aimed at improving health outcomes and disease management. Increasing healthcare expenditure is rising due to the growing adoption of advanced medical treatments, specialized therapies, and modern healthcare technologies, which significantly increase overall patient care costs globally. Increasing healthcare spending supports the EPP treatment by enabling broader access to orphan drugs, advanced diagnostic technologies, specialized care centers, and innovative therapies that improve symptom management and patient quality of life. For instance, in April 2025, according to the American Medical Association, a US-based professional association, in 2023, health spending in the U.S. rose by 7.5%, reaching $4.9 trillion, or $14,570 per person, marking a notable increase compared to the 4.6% growth recorded in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the erythropoietic protoporphyria (EPP) treatment market.

Key companies operating in the erythropoietic protoporphyria (EPP) treatment market are concentrating on the development of advanced disease-modifying therapies aimed at reducing phototoxic reactions, preventing liver complications, and enhancing patient quality of life. Disease-modifying therapies refer to innovative treatments designed to target the underlying cause of EPP by lowering the accumulation of protoporphyrin IX (PPIX), thereby minimizing skin and liver damage associated with exposure to sunlight. For example, in October 2025, GondolaBio, a US-based clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to PORT-77, an investigational oral small-molecule ABCG2 inhibitor developed by its affiliate Portal Therapeutics for the treatment of EPP and X-linked protoporphyria (XLP). The therapy is engineered to rapidly reduce plasma PPIX levels, with the potential to prevent both cutaneous phototoxicity and liver damage. PORT-77 is currently being assessed in a Phase 2A proof-of-concept clinical trial to evaluate its efficacy in improving sunlight tolerance and decreasing disease burden in patients with EPP and XLP.

In May 2024, Clinuvel Pharmaceuticals, an Australia-based biopharmaceutical company focused on delivering treatment for erythropoietic protoporphyria (EPP), formed a collaboration with Valentech Pharma to broaden the availability of SCENESSE (afamelanotide) for patients suffering from erythropoietic protoporphyria (EPP) across the Latin American region. This alliance between Clinuvel Pharmaceuticals and Valentech Pharma is designed to facilitate regulatory access initiatives and commercialization activities related to EPP treatment throughout the LATAM market. Valentech Pharma is a pharmaceutical company based in Colombia that specializes in regulatory affairs and provides commercialization support for innovative therapeutic solutions.

Major companies operating in the erythropoietic protoporphyria (EPP) treatment market are Clinuvel Pharmaceuticals Limited, Mitsubishi Tanabe Pharma Corporation, Disc Medicine Inc., GondolaBio LLC.

North America was the dominant region in the erythropoietic protoporphyria (EPP) treatment market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in erythropoietic protoporphyria (EPP) treatment report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the erythropoietic protoporphyria (EPP) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The erythropoietic protoporphyria (EPP) treatment market consists of revenues earned by entities by providing services such as afamelanotide therapy, liver function monitoring, and pain management support. The market value includes the value of related goods sold by the service provider or included within the service offering. The erythropoietic protoporphyria (EPP) treatment market also includes sales of afamelanotide implants, dersimelagon tablets, bitopertin capsules, and beta carotene supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The erythropoietic protoporphyria (EPP) treatment market research report is one of a series of new reports that provides erythropoietic protoporphyria (EPP) treatment market statistics, including erythropoietic protoporphyria (EPP) treatment industry global market size, regional shares, competitors with a erythropoietic protoporphyria (EPP) treatment market share, detailed erythropoietic protoporphyria (EPP) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the erythropoietic protoporphyria (EPP) treatment industry. This erythropoietic protoporphyria (EPP) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.